Evidence map›Paper›PMID 36416837›Full record

ArticleJAMA ophthalmology2023

Association Between Rate of Ganglion Cell Complex Thinning and Rate of Central Visual Field Loss.

Golnoush Mahmoudinezhad, Sasan Moghimi, Takashi Nishida, Kareem Latif, Maya Yamane, Eleonora Micheletti, Vahid Mohammadzadeh, Jo-Hsuan Wu, Alireza Kamalipour, Elizabeth Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Golnoush MahmoudinezhadHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Sasan MoghimiHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Takashi NishidaHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Kareem LatifHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Maya YamaneHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Eleonora MichelettiHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Vahid MohammadzadehHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Jo-Hsuan WuHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Alireza KamalipourHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Elizabeth LiHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Jeffrey M LiebmannBernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, New York.
Christopher A GirkinDepartment of Ophthalmology and Visual Sciences, Heersink School of Medicine, The University of Alabama at Birmingham.
Massimo A FazioHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Linda M ZangwillHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.
Robert N WeinrebHamilton Glaucoma Center, Shiley Eye Institute, The Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla.

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography AngiographyR01EY029058 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEINREB, ROBERT N · 2018 to 2024
$4.2M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
Age-related changes in optic nerve head structure and biomechanicsR01EY018926 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DOWNS, J CRAWFORD, GIRKIN, CHRISTOPHER ANTHONY · 2008 to 2015
$2.6M
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progressionR01EY026574 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAZIO, MASSIMO ANTONIO, GIRKIN, CHRISTOPHER ANTHONY · 2017 to 2020
$2.6M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY018926NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY026574NEI NIH HHS R01 EY027510NEI NIH HHS R01 EY029058
6 · The paper itself

Abstract

Importance: Whether rapid ganglion cell complex (GCC) thinning during an initial follow-up period is associated with rates of central visual field loss over time is unclear but important to understand because risk of glaucoma progression can help guide treatment intensity. Objective: To investigate the association between the rate of GCC thinning during initial follow-up and the rate of central visual field loss. Design, Setting, and Participants: This retrospective cohort study assessed patients older than 18 years with glaucoma at a tertiary glaucoma center who were followed up from June 18, 2014, to January 11, 2019. Data analysis for the current study was undertaken in March 2022. Main Outcomes and Measures: Initial rates of GCC thinning were obtained from global GCC thickness values of the first 3 optical coherence tomography (OCT) scans. Rates of central visual field loss were assessed as the change in central (10-2) visual field mean deviation during the 4.7-year follow-up period by univariable and multivariable linear mixed-effects models. Eyes were categorized as slow (>-1 μm/y) or fast (≤-1 μm/y) progressors based on rates of GCC thinning. Results: The cohort consisted of 202 eyes of 139 patients (mean [SD] age, 68.7 [10.0] years; 72 male [51.8%]); 44 African American patients (31.7%), 13 Asian patients (9.4%), 80 White patients (57.6%), and 2 patients who identified as other race and ethnicity (1.4%) were analyzed. The rate of GCC change was -0.56 μm/y (95% CI, -0.66 to -0.46 μm/y) during a mean initial follow-up of 1.8 years (95% CI, 1.7-2.0 years). A total of 163 eyes (80.7%) were slow OCT progressors, and 39 (19.3%) were fast OCT progressors, with rates of GCC thinning of -0.3 μm/y (95% CI, -0.4 to -0.2 μm/y) and -1.6 μm/y (-1.8 to -1.3 μm/y), respectively. The rates of 10-2 visual field mean deviation worsening among slow and fast OCT progressors were -0.10 dB/y (95% CI, -0.16 to 0.00 dB/y) and -0.34 dB/y (95% CI, -0.51 to -0.16 dB/y), respectively (difference, -0.26 dB/y; 95% CI, -0.45 to -0.07 dB/y; P = .008). Conclusions and Relevance: In this cohort study, rapid GCC thinning during an initial follow-up period was associated with faster rates of central visual field decline. These findings support use of longitudinal macular OCT scans assisting clinical decision-making for glaucoma and also may guide possible intensification of therapy in high-risk patients.

Indexed as

GlaucomaGlaucoma, Open-AngleOptic DiskAgedCohort StudiesHumansIntraocular PressureMaleNerve FibersRetinal Ganglion CellsRetrospective StudiesScotomaTomography, Optical CoherenceVisual FieldsVisual Field Tests

Identifiers

PMID36416837
PMCPMC9856692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.